Frontiers in cardiovascular medicine · 2025
Predictors of significant tricuspid regurgitation in atrial fibrillation: a meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xiuxiu, Zhang Na, Fu Jia, Yu Dapeng
Аннотация
AIMS: Significant tricuspid regurgitation (TR) in atrial fibrillation (AF) patients is becoming a global issue, as it can lead to progressive right ventricular enlargement and heart failure, thereby increasing morbidity and mortality. This study aimed to evaluate potential predictors of significant TR in AF patients using open databases.
METHODS: PubMed, EMBASE, the Cochrane Library, and Web of Science were searched for relevant studies from inception to September 2023. Using STATA 14.0 statistical software, hazard ratios (HRs) were calculated for data synthesis. The potential predictors included clinical characteristics, echocardiography parameters, and prior comorbidities. Evidence certainty was evaluated based on the GRADE system.
RESULTS: In total, 12 studies involving almost 16,000 patients were included in this review. Female sex (HR = 2.14; 95% CI: 1.84-2.49; I2 = 0.0%; p = 0.430), persistent atrial fibrillation (HR = 2.99; 95% CI: 2.47-3.61; I2 = 0.0%; p = 0.896), left ventricular ejection fraction [standard mean difference (SMD) = -0.16; 95% CI:-0.30 to -0.03; I2 = 69.8%; p < 0.000], age (HR = 1.07; 95% CI: 1.04-1.09; I2 = 72.3%; p = 0.013), heart failure (HR = 1.86; 95% CI: 1.45-2.39; I2 = 9.0%; p = 0.348), age ≥65 years (HR = 2.30; 95% CI: 1.63-3.25; I2 = 55.1%; p = 0.108), chronic lung disease (HR = 1.33; 95% CI: 1.02-1.74; I2 = 0.0%; p = 0.882), right ventricle fractional area change (SMD = 0.18; 95% CI: 0.01-0.36; I2 = 0.0%; p = 0.440), systolic pulmonary arterial pressure (SMD = 0.97; 95% CI: 0.76-1.19; I2 = 41.5%; p = 0.181), and proper ventricular systolic pressure (SMD = 1.07; 95% CI: 0.54-1.59; I2 = 92.4%; p < 0.000) may negatively influence significant TR.
CONCLUSIONS: This meta-analysis identified a potential negative influence of several clinical characteristics, echocardiography parameters, and previous comorbidities on significant TR. However, due to the low level of certainty of evidence, our analysis can only provide some guidance to practitioners and researchers. Caution is advised, and further validation is needed.
METHODS: PubMed, EMBASE, the Cochrane Library, and Web of Science were searched for relevant studies from inception to September 2023. Using STATA 14.0 statistical software, hazard ratios (HRs) were calculated for data synthesis. The potential predictors included clinical characteristics, echocardiography parameters, and prior comorbidities. Evidence certainty was evaluated based on the GRADE system.
RESULTS: In total, 12 studies involving almost 16,000 patients were included in this review. Female sex (HR = 2.14; 95% CI: 1.84-2.49; I2 = 0.0%; p = 0.430), persistent atrial fibrillation (HR = 2.99; 95% CI: 2.47-3.61; I2 = 0.0%; p = 0.896), left ventricular ejection fraction [standard mean difference (SMD) = -0.16; 95% CI:-0.30 to -0.03; I2 = 69.8%; p < 0.000], age (HR = 1.07; 95% CI: 1.04-1.09; I2 = 72.3%; p = 0.013), heart failure (HR = 1.86; 95% CI: 1.45-2.39; I2 = 9.0%; p = 0.348), age ≥65 years (HR = 2.30; 95% CI: 1.63-3.25; I2 = 55.1%; p = 0.108), chronic lung disease (HR = 1.33; 95% CI: 1.02-1.74; I2 = 0.0%; p = 0.882), right ventricle fractional area change (SMD = 0.18; 95% CI: 0.01-0.36; I2 = 0.0%; p = 0.440), systolic pulmonary arterial pressure (SMD = 0.97; 95% CI: 0.76-1.19; I2 = 41.5%; p = 0.181), and proper ventricular systolic pressure (SMD = 1.07; 95% CI: 0.54-1.59; I2 = 92.4%; p < 0.000) may negatively influence significant TR.
CONCLUSIONS: This meta-analysis identified a potential negative influence of several clinical characteristics, echocardiography parameters, and previous comorbidities on significant TR. However, due to the low level of certainty of evidence, our analysis can only provide some guidance to practitioners and researchers. Caution is advised, and further validation is needed.